5806
document
Oral rizatriptan versus oral sumatriptan : a direct comparative study in the acute treatment of migraine . Rizatriptan 030 Study Group . Rizatriptan is a potent , oral , 5-HT1B/1D agonist with more rapid absorption and higher bioavailability than oral sumatriptan . It was postulated that this would result in more rapid onset of effect . This randomized , double-blind , triple-dummy , parallel-groups study compared rizatriptan 5 mg , rizatriptan 10 mg , sumatriptan 100 mg , and placebo in 1268 outpatients treating a single migraine attack . Headache relief rates after rizatriptan 10 mg were consistently higher than sumatriptan at all time points up to 2 hours , with significance at 1 hour ( 37 % versus 28 % , P = 0.010 ) . All active agents were significantly superior to placebo with regard to headache relief and pain freedom at 2 hours ( P < or = 0.001 ) . The primary efficacy endpoint of time to pain relief through 2 hours demonstrated that , after adjustment for age imbalance , rizatriptan 10 mg had earlier onset than sumatriptan 100 mg ( P = 0.032 ; hazard ratio 1.21 ) . Rizatriptan 10 mg was also superior to sumatriptan on pain-free response ( P = 0.032 ) , reduction in functional disability ( P = 0.015 ) , and relief of nausea at 2 hours ( P = 0.010 ) . Significantly fewer drug-related clinical adverse events were reported after rizatriptan 10 mg ( 33 % , P = 0.014 ) compared with sumatriptan 100 mg ( 41 % ) . We conclude that rizatriptan 10 mg has a rapid onset of action and relieves headache and associated symptoms more effectively than sumatriptan 100 mg .
5807
Intervention_Pharmacological
rizatriptan 5 mg , rizatriptan 10 mg , sumatriptan 100 mg
5808
Intervention_Control
placebo
5809
Outcome_Pain
Headache relief rates
5810
Outcome_Pain
headache relief
5811
Outcome_Pain
pain freedom
5812
Outcome_Pain
time to pain relief through 2
5813
Outcome_Physical
reduction in functional disability
5814
Outcome_Physical
relief of nausea
5815
Outcome_Adverse-effects
drug-related clinical adverse events
5816
Participant_Condition
acute treatment of migraine .
5817
Participant_Condition
1268 outpatients treating a single migraine attack .